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Abstract: Cardiovascular and renal disease can be regarded as progressing along a sort of 
continuum which starts with cardiovascular risk factors (hypertension, diabetes, dyslipidemia, 
smoking, etc), evolves with progression of atherosclerotic lesions and organ damage, and then 
becomes clinically manifest with the major clinical syndromes (myocardial infarction, stroke, 
heart failure, end-stage renal disease). The blood pressure control remains a fundamental mecha-
nism for prevention of cardiovascular disease. The renin–angiotensin system is believed to play 
an important role along different steps of the cardiovascular disease continuum. Convincing 
evidence accumulated over the last decade that therapeutic intervention with angiotensin receptor 
blockers (ARBs) is effective to slow down or block the progression of cardiovascular disease at 
different steps of the continuum, with measurable clinical benefits. However, despite the shared 
mechanism of action, each ARB is characterized by specific pharmacological properties that 
may influence its clinical efficacy. Indeed, important differences among available ARBs emerged 
from clinical studies. Therefore, generalization of results obtained with a specific ARB to all 
available ARBs may be misleading. The present review provides a comparative assessment of 
the different ARBs in their efficacy on major clinical endpoints along the different steps of the 
cardiovascular disease continuum.
Keywords: hypertension, renin–angiotensin system, valsartan, telmisartan, irbesartan, losartan, 
olmesartan, eprosartan
According to the chain of events described some years ago by Dzau and Braunwald, 
cardiovascular and renal disease, the most frequent causes of morbidity and mortal-
ity in industrial countries, can be regarded as progressing along a sort of continuum 
(Figure 1).1,2 The continuum starts with cardiovascular risk factors (hypertension, 
diabetes, dyslipidemia, smoking, etc) and evolves with progression of atherosclerotic 
lesions and organ damage. Hence, the continuum may become clinically manifest with 
the major clinical syndromes (myocardial infarction, stroke, heart failure, end-stage 
renal disease), which may ultimately lead to death.1,2
The outcome associated with late stages of the continuum is remarkably poor. For 
example, one out of two patients with New York Heart Association (NYHA) stage IV 
congestive heart failure dies within one year, and approximately 80% of all patients 
with congestive heart failure die within 10 years.3
It is important to note that therapeutic interventions at each step of the continuum 
can slow down or block its progression, with potentially measurable outcome benefits. 
In this setting, the blood pressure control remains a fundamental mechanism for pre-
vention of cardiovascular disease.4Vascular Health and Risk Management 2009:5 940
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Role of the renin–angiotensin 
system
Over the last two decades, a growing number of experimental 
and clinical studies provided evidence of an important role 
played by angiotensin II along the different steps of the cardio-
vascular disease continuum.5 It is well known that angiotensin 
II is produced through the aminoacid cleavage of angiotensin 
I operated by the angiotensin-converting enzyme (ACE) in 
some tissues including the lung, as well as in the myocardium, 
through the effects of specific proteases on angiotensin I.
Angiotensin II raises blood pressure (BP) through direct 
vasoconstriction mediated by AT1 receptor stimulation, and 
sodium and water retention mostly mediated by the stimula-
tion of the synthesis of aldosterone.6 In addition, angiotensin II 
enhances oxidative stress by stimulating NADPH oxidase, with 
consequent generation of reactive oxygen species.7,8 Reactive 
oxygen species, by enhancing inactivation of nitric oxide 
produced by endothelial cells, accelerate the progression of 
atherosclerosis and induce plaque destabilization.7,8 Moreover, 
angiotensin II may trigger intracellular reactions leading to 
myocite and vascular hypertrophy, fibrosis and apoptosis. 
Finally, in patients with chronic congestive heart failure, 
activation of the renin–angiotensin system may contribute to the 
progressive remodeling and dilatation of cardiac chambers.
Stimulation of the AT2 receptors by angiotensin II is 
believed to promote biologic effects that are opposite to 
those of AT1 receptor stimulation. Indeed, AT2 receptor 
stimulation induces vasodilatation and inhibits fibrosis and 
inflammation. Although the effects of AT2 receptor stimula-
tion are complex, the balance is believed to be positive.9
In patients taking ACE-inhibitors, the blunted production 
of angiotensin II and the consequent reduced stimulation of 
AT1- and AT2 receptor may induce an ‘escape phenomenon’, 
which consists in the accumulation of angiotensin I and produc-
tion of angiotensin II through alternative synthetic bio-pathways 
(cathepsine C, chimases).10 This phenomenon, well described 
in patients with congestive heart failure, may be prognostically 
important. For example, the risk of mortality in patients with 
heart failure under chronic treatment with ACE-inhibitors is 
directly related to the circulating levels of angiotensin II.11
Impact of ATs receptor blockade
The above scenario depicts a strong rationale for the 
specific and selective blockade of AT1 receptors through 
specific drugs. Of note, blockade of AT1 receptors is also 
accompanied by an over-stimulation of AT2 receptors by 
angiotensin II. The degree of AT2 stimulation is proportional 
to the selectivity of AT1 blockade.12
Over the last two decades, several AT1 receptor blockers 
(ARBs) have been extensively investigated at different steps 
of the cardiovascular disease continuum (Figure 2). Despite 
the common mechanism of action, each molecule is charac-
terized by a distinct pharmacological profile and a different 
degree of AT1 selectivity, which is highest for valsartan.12 
Obvious economic constrains precluded the executions 
of major outcome-based studies at each step for each of 
the available ARB drugs. On the other hand, however, the 
conclusions of studies conducted in a given clinical setting 
with specific ARBs are hardly applicable to different clinical 
settings or to different ARBs.
In view of the above considerations, the aim of the 
present review was to provide a comparative assessment of 
different ARBs at different steps of the cardiovascular disease 
continuum. Only the principal randomized intervention trials 
Figure 1 Cardiovascular disease continuum. Modified with permission from Dzau  VJ,   Antman EM, Black HR, et al.   The cardiovascular disease continuum validated: clinical evidence 
of improved patient outcomes: part ii: Clinical trial evidence (acute coronary syndromes through renal disease) and future directions. Circulation. 2006;114(25):2871–2891.
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were included in this review. Clinical trials have been retrieved 
from PubMed/MEDLINE using the terms ‘renin–angiotensin 
system’, ‘angiotensin receptor blockers’, ‘hypertension’, 
‘diabetic nephropathy’, ‘stroke’, ‘heart failure’, and ‘left 
ventricular hypertrophy’. We searched for studies published 
in any language up to March 31, 2009.
Hypertension and high 
cardiovascular risk
Arterial hypertension is probably the most important risk fac-
tor for cardiovascular diseases. At any age, there is a positive 
and graded relation between the usual BP and the risk of car-
diovascular and stroke mortality.13 Intervention studies have 
conclusively demonstrated that a relation also exists between 
the degree of BP reduction and the outcome benefit.4,14
In patients with hypertension, the concomitance of addi-
tional risk factors, target organ damage or cardiac and renal 
disease substantially increases the total cardiovascular risk, 
requiring a more aggressive therapeutic approach with more 
stringent treatment goals, in order to prevent further progres-
sion of the cardiovascular continuum.15 In this respect, the role 
of renin–angiotensin system activation even in the early steps 
of the continuum has been confirmed by the positive results 
obtained with different ARBs in terms of reduction of cardio-
vascular morbidity and mortality in different populations.
The Study on Cognition and Prognosis in the Elderly 
(SCOPE) study16 was a double-blind, randomized study 
conducted in 4,964 patients aged 70–89 years, with systolic 
(160–179 mmHg) or diastolic (90–99 mmHg) hypertension 
and a Mini Mental State Examination test score 24. Patients 
were randomized to candesartan titrated to 16 mg once daily 
or placebo on top of other antihypertensive drugs as needed 
by the single patients. Consequently, active drugs were used 
by 84% of patients in the placebo group. The mean duration 
of follow-up was 3.7 years. The primary outcome, a com-
posite of cardiovascular death, nonfatal stroke and nonfatal 
myocardial infarction, occurred in 26.7% of patients in the 
candesartan group and 30.0% of patients in the placebo 
group (risk reduction 10.9%; P = 0.19). Candesartan-based 
treatment reduced nonfatal stroke by 27.8% (95% confidence 
interval [CI]: 1.3 to 47.2; P = 0.04), and all stroke by 23.6% 
(95% CI: -0.7 to 42.1; P = 0.056). There were no differences 
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elderly;   VALiANT,   Valsartan in Acute Myocardial infarction;   Val-HeFT,   Valsartan Heart Failure Trial;  VALUe,  Valsartan Antihypertensive Long-term Use evaluation.Vascular Health and Risk Management 2009:5 942
Verdecchia et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
between the candesartan group and the placebo group with 
regard to dementia, cognitive decline or mean change in Mini 
Mental State Examination test.
The Losartan Intervention for End Point Reduction 
(LIFE) study17 was designed to compare a treatment based 
on losartan with a treatment based on atenolol in patients 
with hypertension and left ventricular (LV) hypertrophy 
diagnosed by electrocardiography. Overall, 9193 patients 
were randomized to losartan titrated to 100 mg daily or 
atenolol titrated to 100 mg daily and followed for a mean 
of 4.8 years. The primary cardiovascular event, a composite 
of death, myocardial infarction, or stroke occurred in 11% of 
patients allocated to losartan and 13% of patients allocated to 
atenolol (P = 0.021) despite a similar reduction of BP in the 
two groups. Stroke was the only component of the primary 
endpoint which was significantly reduced by losartan 
compared to atenolol (5% vs 7%; P = 0.001).
In the Valsartan Antihypertensive Long-term Use Evalu-
ation (VALUE) study,18 15,245 hypertensive patients aged 
50 years or older were randomly allocated in a double-
blind fashion to valsartan (80–160 mg daily) or amlodipine 
(5–10 mg daily). The mean duration of follow-up was 
4.2 years. The primary endpoint was a composite of cardiac 
mortality and morbidity. Although BP was reduced by both 
treatments, the effects of amlodipine were more pronounced, 
especially during the first months of the study. Despite 
the better BP control achieved in the amlodipine group, 
the primary composite endpoint occurred almost equally 
in the two groups (10.6% vs 10.4%; P = 0.49), and the rate 
of fatal and nonfatal stroke (a secondary outcome measure 
of the study) was similar between treatments. New-onset 
diabetes, a prespecified endpoint, occurred at a rate of 
32.1 per 1,000 patient-years in the valsartan group, and 
41.1 per 1,000 patient-years in the amlodipine group (23% 
risk reduction in the valsartan group, P  0.0001).
In the JIKEI study,19 3,081 Japanese patients aged 
between 20 and 79 years (mean, 65 years) who were receiv-
ing a conventional treatment for high BP, coronary heart 
disease or heart failure were randomly assigned to valsartan 
(40–160 mg per day) or to a treatment without ARBs accord-
ing to a prospective, randomized, open-label blinded-endpoint 
(PROBE) design. The primary endpoint was a composite of 
cardiovascular morbidity and mortality (admission to hospital 
for stroke, transient ischemic attack, myocardial infarction, 
congestive heart failure, angina pectoris, dissecting aneurysm 
of the aorta). During a median follow-up of 3.1 years, the 
primary endpoint occurred in 6.0% of patients receiving val-
sartan and 9.7% of patients not receiving ARBs (hazard ratio 
0.61; P = 0.0002). This difference was largely accounted for 
by 40% lower incidence of stroke and TIA in the valsartan 
group compared to the control group (1.9% versus 3.1%; P = 
0.028). In addition, also angina pectoris requiring hospitaliza-
tion (1.2% versus 3.4%; P = 0.0001) and heart failure (1.2% 
versus 2.3%; P = 0.029) were less frequent in the valsartan 
group than in the control group. Mortality did not differ 
between the two groups.
In the Ongoing Telmisartan Alone and in Combination 
with Ramipril Global Endpoint Trial (ONTARGET) study,20 
25,620 patients with a variety of conditions sharing an 
increased vascular risk (history of coronary artery disease, 
cerebrovascular disease, peripheral occlusive disease or 
diabetes with organ damage) were randomized to ramipril 
10 mg daily, telmisartan 80 mg daily or the combination 
of both. Duration of follow-up was five years. The primary 
endpoint, a composite of nonfatal myocardial infarction, 
nonfatal stroke, cardiovascular death or hospitalization 
for heart failure occurred in 16.5% of patients allocated 
to ramipril, 16.7% of patients allocated to telmisartan 
and 16.3% of patients in the combination group. The pre-
specified hypothesis of noninferiority of telmisartan versus 
ramipril was demonstrated (P = 0.001) and the results were 
consistent across the single components of the primary 
outcome. However, the combination of telmisartan and 
ramipril did not differ from ramipril alone (P = 0.38) and 
was associated with a higher incidence of adverse events 
including hypotension, syncope and renal dysfunction.20 
These findings suggest that the degree of renin–angiotensin 
system activation or angiotensin II escape may not have been 
so high in these patients to benefit from a dual blockade of 
the renin–angiotensin system.
Differences among the available ARBs have been docu-
mented in head-to-head comparative studies. In general, the 
new-generation ARBs including irbesartan,21 telmisartan,22 
candesartan,23 and valsartan24 proved more effective than 
losartan in lowering BP in hypertensive patients.
implications in patients with hypertension 
and high cardiovascular risk
Although all ARBs are effective in lowering BP, only a few 
event-based studies have demonstrated the value of this class 
of drugs in reducing cardiovascular events in patients with 
hypertension and high cardiovascular risk. Taken together, 
these studies suggest that:
(a) Losartan demonstrated better efficacy than the beta-
blocker atenolol in reducing cardiovascular morbidity 
and mortality, accounted for by a reduction of stroke.Vascular Health and Risk Management 2009:5 943
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(b) Valsartan demonstrated similar efficacy on cardiovascular 
morbidity and mortality versus amlodipine, despite better 
BP control obtained with the calcium channel blocker. 
When used on top of optimized treatment, valsartan 
induced a reduction of cardiovascular morbidity and 
mortality, accounted for by a positive effect on the occur-
rence of stroke, angina, and heart failure.
(c) Telmisartan was the only ARB which demonstrated thera-
peutic equivalence versus the ACE-inhibitor ramipril.
Myocardial infarction
Patients with acute myocardial infarction frequently present 
with signs and symptoms of heart failure or left ventricular 
dysfunction. In these patients, ACE-inhibitors are effective 
in reducing mortality and morbidity, especially in the subsets 
at higher risk.25
Two major studies tested the hypothesis that an ARB 
was noninferior or superior to an ACE-inhibitor in these 
patients.
In the Optimal Trial in Myocardial Infarction with 
the Angiotensin II Antagonist Losartan (OPTIMAAL),26 
5,477 patients aged 50 years or more (mean age 67 years) 
with acute myocardial infarction and heart failure during 
the acute phase or a new Q-wave anterior infarction or 
reinfarction, were randomized to losartan titrated to 50 mg 
once daily or captopril titrated 50 mg three times daily. The 
primary endpoint was all-cause mortality. The trial was 
designed as a noninferiority trial of losartan versus capto-
pril, with a prespecified right-sided noninferiority margin 
(95% confidence margin) of 1.10. Over a mean follow-up 
of 2.7 years, there were 499 deaths (18%) in the losartan 
group and 447 deaths (16%) in the captopril group (relative 
risk 1.13; 95% CI: 0.99–1.28; P = 0.07). Since the achieved 
upper 95% confidence margin (1.28) was superior to the pre-
specified value of 1.10, the OPTIMAAL trial did not satisfy 
the prespecified criteria for noninferiority of losartan versus 
captopril. As expected, losartan was better tolerated than 
captopril, with fewer patients discontinuing study medication 
(17% vs 23%; P  0.0001).
The Valsartan in Acute Myocardial Infarction (VALIANT) 
trial27 was a double-blind, randomized comparison between 
captopril titrated to 50 mg three times daily, valsartan 
titrated to 160 mg twice daily and their combination in 
14,703 patients with myocardial infarction complicated by 
LV systolic dysfunction, heart failure, or both. The primary 
endpoint was all-cause mortality. Duration of follow-up 
was 24.7 months. The trial was designed as a noninferiority 
trial of valsartan versus captopril, with a prespecified 
upper 97.5% confidence limit of 1.13. During follow-up, 
958 patients died in the captopril group, 979 patients died 
in the valsartan group, and 941 patients died in the valsartan 
plus captopril group. The hazard ratio in the valsartan group 
compared to the captopril group was 1.00 and its 97.5% CI 
ranged between 0.90 and 1.11 (P = 0.98). Therefore, since the 
achieved upper 97.5% confidence margin (1.11) was within 
the prespecified margin of 1.13, the VALIANT study satis-
fied the prespecified criteria for noninferiority of valsartan 
versus captopril (P = 0.004). The valsartan plus captopril 
combination was not superior to captopril alone (P = 0.73) 
and the adverse events, particularly hypotension and renal 
dysfunction, were more frequent in the combination group. 
The statistical techniques of imputing placebo (Figure 3) 
showed that the size of the estimated benefit of valsartan in 
this study was comparable to that observed in three major 
placebo-controlled studies conducted with ACE-inhibitors 
in this kind of patients.
Results of VALIANT are consistent with those of 
ONTARGET in showing the lack of additional outcome 
benefits by the dual blockade of the renin–angiotensin system 
in patients at high vascular risk (ONTARGET) or after myo-
cardial infarction complicated by left ventricular dysfunction 
or heart failure (VALIANT). As discussed above, these data 
suggest that the degree of renin–angiotensin system activa-
tion may be not so high to require a dual blockade in these 
patients.
implications in patients with myocardial 
infarction
The above data suggest that, in patients with myocardial 
infarction and evidence of heart failure of left ventricular 
dysfunction:
(a) Valsartan, titrated up to 160 mg twice daily, provides the 
same benefits, in terms of survival and cardiovascular 
events, as captopril titrated up to 50 mg three times daily
(b) These results can not be extended to losartan 50 mg 
daily, which, contrary to valsartan, failed to demonstrate 
noninferiority versus captopril titrated up to 50 mg three 
times daily in a comparable cohort of patients.
Congestive heart failure
Activation of the renin–angiotensin system is a typical feature 
in chronic heart failure and its inhibition remains an impor-
tant therapeutic target in these patients. However, it has been 
clearly demonstrated that morbidity and mortality remain 
very high in patients with chronic heart failure despite current 
standard medical therapy with diuretics, beta-blockers, Vascular Health and Risk Management 2009:5 944
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ACE-inhibitors, and aldosterone antagonists. The need to 
improve outcome in these patients, as well as the evidence 
of an escape phenomenon to ACE-inhibitors, prompted 
several major trials specifically designed to investigate 
two main aspects: (a) head-to-head comparison between 
ACE-inhibitors and ARBs; (b) assessment of the clinical 
value of complete suppression of the renin angiotensin 
system, as provided by the combination of ACE-inhibitors 
with ARBs, in comparison with either component alone.
Congestive heart failure with reduced  
ejection fraction
In the Evaluation of Losartan in the Elderly (ELITE) study,28 
722 patients with heart failure NYHA class II–IV and ejection 
fraction of 40% or less were randomized to losartan titrated 
to 50 mg once daily or captopril titrated to 50 mg three times 
daily. Duration of follow-up was 48 weeks. The primary 
endpoint was the persisting increase in serum creatinine, the 
secondary endpoint was a composite of death and hospital 
admission for heart failure. While the primary endpoint 
did not differ between the groups, the secondary endpoint 
occurred in 9.4% of patients in the losartan group and 13.2% of 
patients in the captopril group (risk reduction 32%; P = 0.075). 
Total mortality was significantly lower in the losartan group 
(4.8%) than in the captopril group (8.7%) (P = 0.035).
The encouraging results of ELITE study prompted 
the execution of the Evaluation of Losartan in the Elderly 
(ELITE) II Study.29 In this study, 3,152 patients with heart 
failure NYHA class II–IV and LV ejection fraction of 40% or 
less were randomized to losartan titrated 50 mg once daily or 
captopril titrated 50 mg three times daily. The study, planned 
as a superiority trial, was designed to test the hypothesis of a 
30% reduction in mortality in the losartan group with respect 
to captopril. There were no significant differences in all-cause 
mortality between losartan (11.7%) and captopril (10.4%). 
Also the other prespecified endpoints did not differ between 
the groups. Losartan was better tolerated than captopril, as 
suggested by the lower rate of discontinuation due to adverse 
effects (9.7% vs 14.7%; P  0.001). Thus, ELITE II suggested 
that losartan is not superior to captopril in patients with heart 
failure, although it might offer an advantage in patients unable 
to tolerate ACE-inhibitors because of cough or angioedema.
The Valsartan Heart Failure Trial (Val-HeFT)30 was a 
randomized, placebo-controlled, double-blind study between 
valsartan titrated to 160 mg twice daily and placebo in 
5,010 patients with heart failure and LV ejection fraction of 
40% or less. The mean duration of follow-up was 23 months. 
The incidence of primary composite endpoint of mortality 
and morbidity (defined as resuscitated cardiac arrest or 
rehospitalization for heart failure) was lower by 13.2% in the 
Active drug better Placebo better
SAVE study
TRACE study
AIRE study
Combination of
SAVE, TRACE and AIRE
VALIANT study
with imputed placebo
0.5 1.0 2.0 Hazard 
ratio
All-cause mortality
Figure 3 effects on all-cause mortality in trials with ACe-inhibitors and in the VALiANT trial (with imputed placebo) in patients with myocardial infarction and evidence of 
heart failure or left ventricular dysfunction (hazard ratios and 95% confidence intervals). Copyright © 1999.  Modified with permission from Mallion J, Siche J, Lacourciere Y. 
ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. 
J Hum Hypertens. 1999;13(10):657–664.
Abbreviations: SAVE, Survival and Ventricular Enlargement trial;   TRACE, Trandolapril Cardiac Evaluation; AIRE,   Acute Infarction Ramipril Efficacy trial.Vascular Health and Risk Management 2009:5 945
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valsartan group compared to the placebo group (P = 0.009). 
All-cause mortality did not differ between the groups (19.7% 
vs 19.4%). The most frequently used ACE-inhibitors were 
enalapril, lisinopril, captopril, ramipril and quinapril at a 
mean daily dose of 17 mg, 19 mg, 80 mg, 6 mg and 23 mg, 
respectively. The Val-Heft study suggested that a full block-
ade of the renin–angiotensin system by adding valsartan to 
ACE-inhibitors in patients with heart failure and reduced 
ejection fraction reduces the combined endpoint of morbidity 
and mortality. This may be due to the very high degree 
of renin–angiotensin system activation in these patients, 
requiring a dual blockade to be fully reversed. An unexpected 
finding from a post hoc analysis of the Val-Heft study was 
a significant adverse effect of valsartan on outcome in the 
subset of patients who were being treated with both an 
ACE-inhibitor and a beta-blocker at baseline. These find-
ings were not confirmed in the Candesartan in Heart fail-
ure: Assessment of Reduction in Mortality and morbidity 
(CHARM)-ADDED trial, where the effect of candesartan 
were maintained in the subgroup of patients treated with 
beta-blockers.31
The CHARM-ALTERNATIVE study32 compared the 
effects of candesartan, titrated to 32 mg daily, with placebo 
in 2,028 patients with heart failure and LV ejection fraction 
of 40% or less who were both treated at best of their 
condition and intolerant to ACE-inhibitors. As compared 
to placebo, candesartan significantly reduced the primary 
composite endpoint of cardiovascular death or hospita-
lization for heart failure (33% vs 40%, hazard ratio 0.77; 
P = 0.0004) after a median follow-up of 33.7 months. 
All-cause mortality did not differ between the groups.
In the CHARM-ADDED trial,31 2,548 patients with 
heart failure and LV ejection fraction of 40% or less who 
were treated with a background therapy including ACE-
inhibitors and other drugs (but excluding ARBs) were ran-
domized to candesartan titrated to 32 mg daily or placebo. 
The median follow-up was 41 months. Candesartan reduced 
the primary composite outcome (the same as in CHARM-
ALTERNATIVE) by 15% (P = 0.011). However, the rate 
of all-cause mortality did not differ (P = 0.086) between 
candesartan (30%) and placebo (32%). In this study, the 
ACE-inhibitors more frequently used were enalapril, lisino-
pril, captopril and ramipril at a mean daily dose of 17 mg, 
17 mg, 82 mg and 7 mg, respectively. Overall, the study 
suggested that a complete blockade of the renin–angiotensin 
system achieved by adding candesartan to ACE-inhibitors 
is useful in patients with heart failure and reduced ejection 
fraction.
Congestive heart failure with ‘normal’  
ejection fraction
It is well known that ejection fraction is 45% or higher in 
about half of patients with congestive heart failure. The prog-
nostic impact of congestive heart failure with normal ejection 
fraction is controversial, as well as the most appropriate 
treatment in these patients.
In the CHARM-PRESERVED study,33 3,023 patients 
with chronic heart failure and LV ejection fraction greater 
than 40% were randomized to candesartan titrated to 32 mg 
daily or placebo on top of their background therapy. The 
primary outcome was cardiovascular death or admission to 
hospital for congestive heart failure. Duration of follow-up 
was 37 months. The incidence of primary outcome was 22% 
with candesartan and 24% with placebo (P = 0.118). While 
cardiovascular death did not differ between the groups, fewer 
patients in the candesartan group had a new hospitalization for 
re-exacerbation of heart failure once (230 vs 279; P = 0.017). 
About 19% of patients received also an ACE-inhibitor, 55% 
a beta-blocker and 11% received spironolactone.
The Irbesartan in Heart Failure with Preserved Ejection 
Fraction Study (I-PRESERVE)34 was a comparative 
study between irbesartan 300 mg daily and placebo in 
4,128 patients aged 60 years or more and heart failure 
with LV ejection fraction greater than 40%. Duration 
of follow-up was 49.5 months. The primary composite 
endpoint (all-cause death or hospitalization for heart failure, 
myocardial infarction, unstable angina, arrhythmia, or 
stroke) occurred in 742 (36.0%) patients in the irbesartan 
group and 763 (37.0%) in the placebo group (P = 0.35). 
All-cause mortality and the rate of hospitalization did 
not differ between the groups (P = 0.98 and P = 0.44, 
respectively). There were no significant differences in the 
other prespecified endpoints. Interestingly, about 25% of 
patients received an ACE-inhibitor, 58% a beta-blocker and 
15% received spironolactone.
implications in patients with heart failure
Taken together, these data suggest that, in patients with 
chronic congestive heart failure, reduced ejection fraction 
and concomitant treatment with ACE-inhibitors:
(a) Losartan was not superior to captopril in reducing all-
cause mortality or cardiovascular events. The relatively 
low dose of losartan (50 mg) may contribute to explain 
these results.
(b) The combined blockade of the renin–angiotensin sys-
tem achieved by valsartan titrated to 320 mg daily, 
or candesartan titrated to 32 mg daily, in addition to Vascular Health and Risk Management 2009:5 946
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ACE-inhibitors, reduced the composite endpoint of 
all-cause mortality and hospitalization for heart failure. 
These data suggest that an incomplete blockade of the 
renin–angiotensin system, possibly associated with the 
‘escape’ phenomenon under ACE-inhibition, may be an 
important basic mechanism explaining the high risk of 
morbidity and mortality in these patients.
(c) Since none of the other available ARBs has been inves-
tigated in outcome-based studies in these patients with 
poor short- and long-term outcome, extrapolation of 
results obtained with valsartan and candesartan to other 
ARBs should not be allowed.
Conversely, as resulting from studies with candesartan 
and irbesartan, there is no evidence that AT1 blockade 
reduces the primary outcome of morbidity and mortality in 
patients with chronic heart failure and preserved ejection 
fraction, although a modest benefit with candesartan may be 
observed in terms of fewer hospitalization for heart failure.
Diabetic nephropathy
Approximately 40% of patients with type 2 diabetes develop 
nephropathy, which is the main determinant of end-stage 
renal disease. Prevention, early identification and appropriate 
treatment of nephropathy in these patients are therefore of 
vital importance. Reduction of proteinuria is associated 
with renal and cardiovascular protection. There is large 
evidence from animal and human studies that inhibition of 
the renin–angiotensin system reduces proteinuria.35,36
In this setting, the evidence that ACE-inhibitors reduce 
proteinuria and slow the progression of renal damage in 
patients with type 1 diabetes can not be extrapolated to 
patients with type 2 diabetes because of the substantial 
differences between these two groups of patients in terms of 
potential mechanisms of glomerular disease and demographic 
and metabolic features. Over the last decade, several studies 
conducted with ARBs in patients with type 2 diabetes 
provided important data for a better management of these 
patients. In particular, three major trials were conducted in 
patients with type 2 diabetes and early (one study) or more 
advanced (two studies) nephropathy.
In the Irbesartan in Patients with Type 2 Diabetes and 
Microalbuminuria (IRMA) study,37 590 hypertensive patients 
with type 2 diabetes and early nephropathy (defined by 
microalbuminuria) were randomized to placebo, irbesartan 
150 mg or irbesartan 300 mg on top of background therapy 
and followed for two years. The primary outcome was the 
time to onset of diabetic nephropathy, defined by persistent 
albuminuria (200 µg per minute). The primary endpoint 
was achieved by 14.9% of patients with placebo, 9.7% of 
patients with irbesartan 150 mg (P = 0.08) and 5.2% of 
patients with irbesartan 300 mg (P = 0.001). These effects 
were independent of BP changes.
In the Reduction of Endpoints in NIDDM with the 
Angiotensin II Antagonist Losartan (RENAAL) study,38 
1,513 patients with type 2 diabetes and nephropathy were 
randomized to losartan titrated to 100 mg per day, or placebo, 
on top of conventional treatment. Follow-up lasted a mean 
of 3.4 years. The primary outcome, a composite of doubling 
of the baseline serum creatinine, end-stage renal disease, or 
death occurred in 43.5% of patients in the losartan group and 
47.1% of patients in the placebo group (16% risk reduction, 
P = 0.02).
The Irbesartan Diabetic Nephropathy Trial (IDNT)39 was 
a randomized, double-blind comparison between irbesartan 
300 mg, amlodipine 10 mg and placebo in 1,715 hypertensive 
patients with type 2 diabetes and established nephropathy 
with macroproteinuria. Duration of follow-up was 2.6 years. 
The incidence of a primary composite endpoint consisting 
of doubling of serum creatinine, development of end-stage 
renal disease, or death from any cause, was reduced by 
20% with irbesartan compared to placebo (P = 0.02), 
and by 23% with irbesartan compared to amlodipine 
(P = 0.006). Similarly to the IRMA study, these differences 
were not explained by differences in achieved BP between 
the treatments. There were no significant differences 
between the groups in the rate of death from any cause or 
cardiovascular events.
implications in patients with diabetes  
and nephropathy
Overall, these data suggest that: in patients with type 2 diabetes 
and early nephropathy (microalbuminuria), irbesartan 300 mg 
is more effective than placebo in preventing the progression 
to macroproteinuria. In patients with type 2 diabetes and 
more advanced nephropathy (macroproteinuria), losartan is 
more effective than placebo, and irbesartan more effective 
than placebo and amlodipine, in preventing the composite 
outcome of end-stage renal disease, doubling of serum cre-
atinine or death.
Conclusions
The overall message of the trials examined in this review 
is that intervention with ARBs at different steps of the car-
diovascular disease continuum is effective to slow down or 
block the disease progression, with consequent measurable 
benefits. However, generalization of results to all available Vascular Health and Risk Management 2009:5 947
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ARBs for any step of the continuum may be misleading 
because differences among available ARBs emerged from 
these studies.
In deciding the choice of the ARB in the individual patient 
along specific steps of the cardiovascular disease continuum, 
the driving concept should be that, despite the shared mecha-
nism of action, each molecule is characterized by specific 
pharmacological properties that are likely to influence its 
clinical efficacy. Therefore, according to the principles of 
evidence-based-medicine, the tempting attitude of applying 
conclusions of studies conducted in specific clinical settings 
with a specific ARB to different contexts or to different ARBs 
should be avoided. The simple conclusion bullets outlined 
below may help in driving our clinical choices.
(a) Valsartan on top of optimized pharmacological therapy 
reduced the risk of cardiovascular events and, in particular, 
the risk of stroke in patients with high cardiovascular 
risk. In patients with heart failure and LV dysfunction, 
valsartan on top of optimized therapy including an 
ACE-inhibitor, significantly reduced morbidity/mortality 
combined endpoint and significantly reduced the rate 
of re-hospitalization due to worsening of heart failure, 
thereby improving quality of life in these patients and 
reducing health care costs. In patients with myocar-
dial infarction complicated by heart failure or LV 
dysfunction, alone or combined, valsartan was the sole 
ARB which reduced morbidity and mortality, with a 
protective effect similar to the ACE-inhibitor comparator 
captopril. Valsartan is therefore the ARB with the largest 
scientific documentation along the different steps of 
the cardiovascular disease continuum.
(b) Losartan was superior to the beta-blocker atenolol in 
reducing the risk of stroke in patients with hypertension 
and LV hypertrophy. In patients with type 2 diabetes and 
nephropathy, losartan in addition to conventional therapy 
reduced proteinuria and the progression to end stage renal 
disease. In patients with chronic heart failure, losartan 
proved to be an alternative therapeutic option in patients 
intolerant to ACE-inhibitors.
(c) Candesartan on top of optimized pharmacological 
therapy reduced morbidity and mortality, as well as the 
rehospitalization rate, in patients with heart failure and 
LV dysfunction.
(d) Irbesartan reduced proteinuria and progression to end 
stage renal disease in patients with type 2 diabetes and 
nephropathy.
(e) Telmisartan reduced cardiovascular events in a broad 
population of patients with high cardiovascular risk, 
with a protective effect similar to the ACE-inhibitor 
comparator ramipril.
(f) Other ARBs, although effective in reducing BP levels, 
are not supported by event-based studies dealing with 
cardiac or renal end organ protection.
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